stockrow
Friday 6 November 2026
Export PODD’s income statement to Excel — free account
Insulet Corporation
PODD Healthcare Medical Devices
Insulet Corporation’s revenue for fiscal 2025 (year ended December 2025) was $2.7 billion, up 30.7% from fiscal 2024.
- Revenue
- +19.2%
- EPS
- +64.1%
- Free cash flow
- −29.8%
- Total debt
- −5.19%
Quarter to September 2026, against a year earlier
146.38
9.74
−6.24%
Follow PODD
Alert me
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
81.21 | 43.66 | 70.88 | 4,091.14 | 1,156.83 | 2,323.91 | 951.11 | 1,322.00 | 0.00 | 0.00 |
Piotroski F-Score |
6 | 8 | 6 | 4 | 4 | 5 | 5 | 6 | 5 | 6 |
P/S ratio |
7.38 | 8.83 | 8.59 | 15.22 | 16.39 | 18.30 | 14.05 | 8.28 | 8.63 | 5.83 |
Altman Z-Score |
9.09 | 7.40 | 6.15 | 7.68 | 8.18 | 8.56 | 6.26 | 4.03 | 3.64 | 2.76 |
P/FCF ratio |
57.15 | 61.76 | 399.61 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
4.78 | 4.29 | 3.38 | 2.31 | 3.30 | 3.17 | 0.94 | 0.55 | 0.99 | (0.33) |
Beneish M-Score |
(2.59) | (2.35) | (1.85) | (2.18) | (1.72) | (2.49) | (3.07) | (2.17) | (1.56) | (3.23) |
P/Operating CF |
109.09 | 124.03 | 322.69 | 391.87 | (706.37) | 973.42 | 221.19 | 153.38 | 182.81 | 106.54 |
P/B ratio |
13.20 | 15.10 | 19.91 | 41.70 | 32.38 | 27.42 | 136.68 | 22.01 | 25.25 | 33.86 |
Price to Tangible BV |
14.85 | 17.23 | 25.05 | 56.89 | 37.53 | 30.93 | 453.00 | 28.80 | 35.01 | 99.77 |
EV/Sales |
7.47 | 9.04 | 9.01 | 15.78 | 16.83 | 18.42 | 14.75 | 8.86 | 8.95 | 5.98 |
EV/EBITDA |
35.85 | 48.04 | 52.23 | 204.31 | 100.84 | 155.85 | 139.79 | 116.18 | 638.80 | 701.95 |
EV/Operating CF |
35.53 | 43.52 | 104.99 | 173.06 | (271.58) | 198.33 | 110.67 | 139.16 | 100.54 | 138.04 |
EV/FCF |
57.81 | 63.20 | 419.10 | (537.72) | (96.93) | (201.94) | (150.20) | (38.46) | (127.76) | (354.03) |
Quick Ratio |
1.81 | 2.50 | 2.36 | 2.41 | 4.16 | 5.02 | 2.82 | 3.16 | 5.74 | 5.88 |
Current Ratio |
2.81 | 3.58 | 3.51 | 3.60 | 5.81 | 6.01 | 3.75 | 3.99 | 6.24 | 6.64 |
Net Debt/EBITDA |
0.41 | 1.09 | 2.43 | 7.21 | 2.63 | 1.04 | 6.62 | 7.05 | 19.40 | 10.93 |
Debt/Assets |
29.75% | 44.69% | 54.70% | 62.27% | 62.18% | 56.56% | 78.04% | 63.75% | 69.32% | 72.87% |
Debt/Equity |
0.63 | 1.14 | 1.93 | 2.94 | 2.29 | 1.76 | 11.75 | 2.79 | 3.57 | 5.27 |
Asset Turnover |
0.86 | 0.73 | 0.70 | 0.61 | 0.56 | 0.60 | 0.71 | 0.65 | 0.73 | 1.00 |
Operating CF/Net income |
2.30 | 1.03 | 0.71 | 25.87 | (4.05) | 12.35 | 8.48 | 10.88 | (1.54) | (0.55) |
Capex/Depreciation |
(2.43) | (1.66) | (1.50) | (2.49) | (2.14) | (3.01) | (6.13) | (10.41) | (5.55) | (1.60) |
Interest Coverage |
7.98 | 7.23 | 6.08 | 1.04 | 2.04 | 1.14 | 1.81 | 1.29 | (0.35) | (0.74) |
| 18.12% | 43.03% | 34.12% | 0.89% | 2.90% | 2.00% | 8.06% | 1.78% | (24.18%) | (59.42%) | |
| 7.87% | 14.74% | 8.53% | 0.21% | 0.86% | 0.45% | 1.12% | 0.38% | (4.21%) | (7.89%) | |
ROIC |
16.94% | 11.79% | 9.52% | 1.95% | 7.58% | 4.50% | 5.28% | 3.32% | (1.62%) | (6.87%) |
Return on Tangible Assets |
12.03% | 20.05% | 11.48% | 0.30% | 1.03% | 0.45% | 1.39% | 0.55% | (4.79%) | (8.04%) |
Average Days of Receivables |
69.67 | 64.40 | 77.36 | 57.49 | 53.48 | 38.46 | 34.27 | 49.66 | 42.00 | 28.65 |
Research and Development Expense of Revenue |
11.12% | 10.60% | 12.08% | 13.81% | 14.57% | 16.23% | 17.92% | 15.79% | 16.32% | 15.18% |
Selling, General and Administrative Expense of Revenue |
43.02% | 44.27% | 43.30% | 45.03% | 42.41% | 42.46% | 40.37% | 43.99% | 45.04% | 45.25% |
Intangible Assets out of Total Assets |
0.05 | 0.05 | 0.06 | 0.06 | 0.04 | 0.04 | 0.05 | 0.05 | 0.05 | 0.09 |
Share Based Compensation of Revenue |
2.32% | 3.35% | 2.85% | 3.13% | 3.13% | 3.97% | 3.89% | 6.65% | 6.88% | 6.44% |
Graham Net Nets |
0.01 | 0.00 | (0.02) | (0.02) | (0.01) | 0.00 | (0.05) | (0.05) | (0.03) | (0.01) |
Graham Number |
41.19 | 48.23 | 26.41 | 3.29 | 6.52 | 4.80 | 2.25 | 2.21 | 0.00 | 0.00 |
Earnings Yield |
1.23% | 2.29% | 1.41% | 0.02% | 0.09% | 0.04% | 0.11% | 0.08% | (0.67%) | (1.37%) |
Free Cash Flow Yield |
1.75% | 1.62% | 0.25% | (0.19%) | (1.06%) | (0.50%) | (0.70%) | (2.78%) | (0.81%) | (0.29%) |
Revenue per Share |
38.50 | 29.56 | 24.33 | 18.82 | 16.23 | 13.97 | 12.18 | 9.58 | 8.00 | 6.41 |
Operating CF per Share |
8.09 | 6.14 | 2.09 | 1.72 | (1.01) | 1.30 | 1.62 | 0.61 | 0.71 | 0.28 |
Capex per Share |
(3.12) | (1.91) | (1.57) | (2.27) | (1.81) | (2.57) | (2.82) | (2.76) | (1.33) | (0.39) |
Free Cash Flow per Share |
4.97 | 4.23 | 0.52 | (0.55) | (2.82) | (1.27) | (1.20) | (2.15) | (0.62) | (0.11) |
Cash per Share |
10.18 | 13.61 | 10.10 | 9.73 | 11.69 | 14.64 | 6.21 | 4.91 | 7.59 | 5.22 |
Shareholders Equity per Share |
21.54 | 17.29 | 10.50 | 6.87 | 8.22 | 9.32 | 1.25 | 3.60 | 2.73 | 1.10 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
21.54 | 17.29 | 10.50 | 6.87 | 8.22 | 9.32 | 1.25 | 3.60 | 2.73 | 1.10 |
Free Cash Flow |
349.90 | 296.20 | 36.50 | (38.30) | (190.80) | (82.50) | (72.50) | (126.50) | (35.90) | (6.20) |
Working Capital |
1,233.90 | 1,362.90 | 1,131.70 | 949.30 | 1,101.00 | 1,040.90 | 433.30 | 345.60 | 451.15 | 314.26 |
Capital Expenditures |
(219.40) | (134.00) | (109.20) | (157.30) | (122.70) | (166.50) | (170.90) | (162.40) | (77.20) | (22.11) |
Net Current Asset Value |
238.80 | 15.20 | (272.60) | (460.70) | (162.70) | (20.60) | (476.00) | (255.30) | (121.06) | (23.54) |
EV/EBIT |
42.69 | 60.61 | 69.50 | 547.73 | 146.78 | 323.49 | 217.79 | 187.68 | 0.00 | 0.00 |
Capex to Sales |
0.08 | 0.06 | 0.06 | 0.12 | 0.11 | 0.18 | 0.23 | 0.29 | 0.17 | 0.06 |
Price to Operating Income |
42.20 | 59.23 | 66.27 | 528.39 | 142.96 | 321.32 | 207.47 | 175.39 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.11 | 0.11 | 0.11 | 0.11 | 0.11 | 0.12 | 0.07 | 0.06 | 0.13 | 0.31 |
Cash ROIC |
11.00% | 8.36% | 1.28% | (1.50%) | (7.28%) | (3.16%) | (5.39%) | (11.57%) | (3.08%) | (0.89%) |
Accounts Receivable Turnover |
6.14 | 5.71 | 6.00 | 7.12 | 8.57 | 10.99 | 10.11 | 8.67 | 11.29 | 10.29 |
Accounts Payable Turnover |
16.21 | 32.10 | 21.49 | 14.59 | 7.55 | 5.93 | 6.45 | 7.76 | 9.93 | 10.99 |
Inventory Turnover |
1.74 | 1.50 | 1.43 | 1.54 | 1.52 | 2.52 | 2.99 | 3.68 | 5.38 | 6.56 |
Average Days of Payables |
35.64 | 11.55 | 13.05 | 22.50 | 39.69 | 61.31 | 77.13 | 48.08 | 47.75 | 30.81 |
Days of Inventory on Hand |
215.05 | 250.99 | 273.55 | 253.32 | 319.20 | 174.85 | 142.94 | 134.61 | 66.10 | 83.15 |
Average Receivables |
441.20 | 362.60 | 282.65 | 183.30 | 128.15 | 82.30 | 73.00 | 65.04 | 41.09 | 35.67 |
Average Payables |
47.40 | 19.50 | 25.00 | 34.25 | 45.90 | 54.30 | 40.00 | 24.96 | 18.79 | 14.19 |
Average Inventory |
441.50 | 416.50 | 374.70 | 325.00 | 228.75 | 127.65 | 86.20 | 52.60 | 34.65 | 23.77 |
Average Assets |
3,139.05 | 2,837.95 | 2,419.65 | 2,149.95 | 1,960.85 | 1,507.90 | 1,035.80 | 872.72 | 636.70 | 365.89 |
Average Common Equity |
1,363.45 | 972.15 | 604.55 | 516.35 | 579.95 | 339.75 | 144.00 | 185.31 | 110.83 | 48.60 |
Columns are period end dates · fundamentals updated 5 Nov 2026